DMW – Klinischer Fortschritt, Table of Contents Dtsch Med Wochenschr 2011; 136(40): 2025-2028DOI: 10.1055/s-0031-1286386 Nephrologie | Commentary Nephrologie © Georg Thieme Verlag KG Stuttgart · New York Dialysetherapie und Nierentransplantation Dialysis therapy and renal transplantationW. Riegel1 , P. Schnülle2 1Medizinische Klinik III, Klinikum Darmstadt 2V. Medizinische Klinik, Universitätsmedizin Mannheim Recommend Article Abstract Buy Article Schlüsselwörter chronisches Nierenversagen - Dialyse - Peritonealdialyse - Nierentransplantation Keywords chronic renal failure - dialysis - peritoneal dialysis - renal transplantation Full Text References Literatur 1 Budde K. et al, ZEUS Study Investigators . Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants. Lancet. 2011; 377 837-847 2 Cooper B A, Branley P, Bulfone L. et al, IDEAL Study . A randomized, controlled trail of early versus late initiation of dialysis. N Engl J Med. 2010; 363 609-619 3 Covic A, Bammens B, Lobbedez T. et al . Educating end-stage renal disease patients on dialysis modality selection: a clinical advice from the European Renal Best Practice (ERBP) Advisory Board. NDT Plus. 2010; 3 225-233 4 Culleton B F, Walsh M, Klarenbach S W. et al . Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life. JAMA. 2007; 298 1291-1299 5 Durrbach A, Pestana J M, Pearson T. et al . A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010; 10 547-557 6 Ekberg H, Tedesco-Silva H, Demirbas A. et al, for the ELITE-Symphony Study . Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357 2562-2575 7 Hanaway M J, Woodle E S, Mulgaonkar S. et al, INTAC Study Group . Alemtuzumab induction in renal transplantation. N Engl J Med. 2011; 364 1909-1919 8 Jefferies H J, Virk B, Schiller B, Moran J, McIntyre C W. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol. 2011; 6 1326-1332 9 Kainz A, Wilflingseder J, Mitterbauer C. et al . Steroid pretreatment of organ donors to prevent postischemic renal allograft failure. Ann Intern Med. 2010; 153 222-230 10 Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group . KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9 (Suppl 3) S1-157 11 Kooienga L. Phosphorus balance with daily dialysis. Semin Dial. 2007; 20 342-345 12 Lebranchu Y, Thierry A, Toupance O. et al . Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant. 2009; 9 1115-1123 13 Marenzi G, Lauri G, Grazi M. et al . Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol. 2001; 38 963 14 Rosansky S, Glassock R J, Clark W F. Early start of dialysis. J Am Soc Nephrol. 2011; 6 1222-1228 15 Schnuelle P, Gottmann U, Hoeger S. et al . Effects of donor pretreatment with dopamine on graft function after kidney transplantation. JAMA. 2009; 302 1067-1075 16 Stock P G, Barin B, Murphy B. et al . Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010; 363 2004-2014 17 Unruh M. Sleep apnoea and dialysis therapies: things that go bump in the night?. Hemodial Int. 2007; 11 369-378 18 Vincenti F, Charpentier B, Vanrenterghem Y. et al . A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010; 10 535-546 19 Weir M R, Mulgaonkar S, Chan L. et al . Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation. Kidney Int. 2011; 79 897-907 Prof. Dr. med. Werner Riegel Medizinische Klinik IIIKlinikum Darmstadt Grafenstr. 9 64283 Darmstadt
